Allogeneic stem cell transplant for adults with myelodysplastic syndromes: relevance of pre-transplant disease status

References

• Valent P, Horny HP, Bennett JM, et al. Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: consensus statements and report from a working conference. Leuk Res 2007;31:727–736.
   PubMed Web of Science ®Google Scholar
• Cutler CS, Lee SJ, Greenberg P, et al. A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome. Blood 2004;104:579–585.
   PubMed Web of Science ®Google Scholar
• Sorror ML, Sandmaier BM, Storer BE, et al. Comorbidity and disease status based risk stratification of outcomes among patients with acute myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic cell transplantation. J Clin Oncol 2007; 25:4246–4254.
   PubMed Web of Science ®Google Scholar
• Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors. Transplantation 1974;18:295–304.
   PubMed Web of Science ®Google Scholar
• Shulman HM, Sullivan KM, Weiden PL. Chronic graft-versus-host syndrome in man: a long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980;69:204–217.
   PubMed Web of Science ®Google Scholar
• Gooley TA, Leisenring W, Crowley J, et al. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med 1999;18:695–706.
   PubMed Web of Science ®Google Scholar
• Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457–481.
   Web of Science ®Google Scholar
• Nevill TJ, Shepherd JD, Sutherland HJ, et al. IPSS poor-risk karyotype as a predictor of outcome for patients with myelodysplastic syndrome following myeloablative stem cell transplantation. Biol Blood Marrow Transplant 2009;15:205–213.
   PubMed Web of Science ®Google Scholar
• Warlick ED, Cioc A, Defor T, et al. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden. Biol Blood Marrow Transplant 2009;15:30–38.
   PubMed Web of Science ®Google Scholar
• Kindwall-Keller T, Isola LM. The evolution of hematopoietic SCT in myelodysplastic syndrome. Bone Marrow Transplant 2009; 43:597–609.
   PubMed Web of Science ®Google Scholar
• De Lima M, Anagnostopoulos A, Munsell M, et al. Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation. Blood 2004;104:865–872.
   PubMed Web of Science ®Google Scholar
• Shimoni A, Hardan I, Shem-Tov N, et al. Allogeneic hematopoietic stem-cell transplanation in AML and MDS using myeloablative versus reduced-intensity conditioning: long-term follow-up. Leukemia 2010: 24;1050–1052.
   PubMed Web of Science ®Google Scholar
• Alyea EP, Kim HT, Ho V, et al. Impact of conditioning regimen intensity on outcome of allogeneic hematopoietic cell transplantation for advanced acute myelogenous leukemia and myelodysplastic syndrome. Biol Blood Marrow Transplant 2006;12:1047–1055.
   PubMed Web of Science ®Google Scholar
• Tauro S, Craddock C, Peggs K, et al. Allogeneic stem-cell transplantation using a reduced-intensity conditioning regimen has the capacity to produce durable remissions and long-term disease-free survival in patients with high-risk acute myeloid leukaemia and myelodysplasia. J Clin Oncol 2005;23:9387–9393.
   PubMed Web of Science ®Google Scholar
• Weisdorf D, Zhang M, Arora M, et al. Graft-versus-host disease induced graft-versus-leukemia effect: greater impact on relapse and disease free survival after reduced intensity conditioning. Biol Blood Marrow Transplant 2012;18:1727–1733.
   PubMed Web of Science ®Google Scholar
• Boehm A, Sperr WR, Leitner G, et al. Comorbidity predicts survival in myelodysplastic syndromes or secondary acute myeloid leukemia after allogeneic stem cell transplantation. Eur J Clin Invest 2008;38:945–952.
   PubMed Web of Science ®Google Scholar
• Zipperer E, Pelz D, Nachtkamp K, et al. The hematopoietic stem cell transplantation comorbidity index is of prognostic relevance for patients with myelodysplastic syndrome. Haematologica 2009; 94:729–732.
   PubMed Web of Science ®Google Scholar
• Guardiola P, Runde V, Bacigalupo , et al. Retrospective comparison of bone marrow and granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells for allogeneic stem cell transplantation using HLA identical sibling donors in myelodysplastic syndromes. Blood 2002;99:4370–4378.
   PubMed Web of Science ®Google Scholar
• Del Canizo MC, Martınez C, Conde E, et al. Peripheral blood is safer than bone marrow as a source of hematopoietic progenitors in patients with myelodysplastic syndromes who receive an allogeneic transplantation. Results from the Spanish registry. Bone Marrow Transplant 2003;32:987–992.
   PubMed Web of Science ®Google Scholar
• Oran B, Giralt S, Saliba R, et al. Allogeneic hematopoietic stem cell transplantation for the treatment of high-risk acute myelogenous leukemia and myelodysplastic syndrome using reduced-intensity conditioning with fludarabine and melphalan. Biol Blood Marrow Transplant 2007;13:454–462.
   PubMed Web of Science ®Google Scholar
• Bokhari SW, Watson L, Nagra S, et al. Role of HCT comorbidity index, age and disease status at transplantation in predicting survival and non-relapse mortality in patients with myelodysplasia and leukemia undergoing reduced-intensity-conditioning hemopoietic progenitor cell transplantation. Bone Marrow Transplant 2012;47: 528–534.
   PubMed Web of Science ®Google Scholar
• Scott BL, Storer B, Loken MR, et al. Pretransplantation induction chemotherapy and posttransplantation relapse in patients with advanced myelodysplastic syndrome. Biol Blood Marrow Transplant 2005;11:65–73.
   PubMed Web of Science ®Google Scholar
• Nakai N, Kanda Y, Fukuhara S, et al. Value of chemotherapy before allogeneic hematopoietic stem cell transplantation from an HLA-identical sibling donor for myelodysplastic syndrome. Leukemia 2005;19:396–401.
   PubMed Web of Science ®Google Scholar
• Damaj G, Duhamel A, Robin M, et al. Impact of azacitidine before allogeneic stem-cell transplantation for myelodysplastic syndromes: a study by the Societé Francaise de Greffe de Moelle et de Therapie-Cellulaire and the Groupe-Francophone des Myelodysplasies. J Clin Oncol 2012;30:4533–4540.
   PubMed Web of Science ®Google Scholar
• Gerds AT, Gooley TA, Estey EH, et al. Pretransplantation therapy with azacitidine vs induction chemotherapy and posttransplantation outcome in patients with MDS. Biol Blood Marrow Transplant 2012;18:1211–1218.
   PubMed Web of Science ®Google Scholar
• Mollgard L, Saft L, Treppendahl B, et al. Clinical effect of increasing doses of lenalidomide in high-risk myelodysplastic syndrome and acute myeloid leukaemia with chromosome 5 abnormalities. Haematologica 2011;96:963–971.
   PubMed Web of Science ®Google Scholar
• Platzbecker U, Schetelig J, Finke J, et al. Allogeneic haematopoietic cell transplantation in patients age 60–70 years with de novo high-risk myelodysplastic syndrome or secondary acute myelogenous leukaemia: comparision with patients lacking donors who received azacitidine. Biol Blood Marrow Transplant 2012;18: 1415–1421.
   PubMed Web of Science ®Google Scholar
• Jabbour E, Giralt S, Kantarjian H, et al. Low-dose azacitidine after allogeneic stem cell transplantation for acute leukaemia. Cancer 2009;115:1899–1905.
   PubMed Web of Science ®Google Scholar
• Sockel K, Bornhaeuser M, Mischak Weissinger E, et al. Lenalidomide maintenance after allogeneic HSCT seems to trigger acute graft-versus-host disease in patients with high-risk myelodysplastic syndromes or acute myeloid leukaemia and del(5q): results of the LENAMAINT trial. Haematologica 2012;97:e34–e35.
   PubMed Web of Science ®Google Scholar
• Ringden O, Horowitz MM, Sondel P, et al. Methotrexate, cyclosporine, or both to prevent graft-versus-host disease after HLA-identical sibling bone marrow transplants for early leukemia. Blood 1993;81:1094–1101.
   PubMed Web of Science ®Google Scholar
• Einsele H, Ehninger G, Hebart H, et al. Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side effects of antiviral therapy after bone marrow transplantation. Blood 1995;86:2815–2820.
   PubMed Web of Science ®Google Scholar
• El-Cheikh J, Crocchiolo R, Boher JM, et al. Comparable outcomes between unrelated and related donors after reduced-intensity conditioning allogeneic hematopoietic stem cell transplantation in patients with high-risk multiple myeloma. Eur J Haematol 2012;88: 497–503.
   PubMed Web of Science ®Google Scholar